MAP1LC3B2: A Protein Involved in Cellular Processes and Potential Drug Target

Target Name: MAP1LC3B2

NCBI ID: G643246

MAP1LC3B2

Other Name(s): Microtubule-associated proteins 1A/1B light chain 3B-like | Microtubule associated protein 1 light chain 3 beta 2 | MP3B2_HUMAN | microtubule associated protein 1 light chain 3 beta 2 | Microtubule-associated proteins 1A/1B light chain 3B-like protein | ATG8G | Microtubule-associated proteins 1A/1B light chain 3 beta 2

MAP1LC3B2: A Protein Involved in Cellular Processes and Potential Drug Target

MAP1LC3B2 is a protein that is expressed in a variety of tissues throughout the body, including muscle, brain, and heart. It is a member of the Microtubule-associated proteins (MAPs) family, which are known for their role in the structure and function of microtubules, the protein-protein interaction networks that exist within eukaryotic cells.

MAP1LC3B2 is characterized by its localization to the microtubules of the cell. It is primarily expressed in the cytosol of the cell and is also found in the endoplasmic reticulum (ER) and in the nuclear pore complex (NPC). This suggests that it is involved in the regulation of microtubule dynamics and stability.

MAP1LC3B2 is a protein that has been shown to play a role in a variety of cellular processes. For example, it has been shown to be involved in the regulation of muscle contractions, and in the control of cell division. It has also been shown to play a role in the regulation of the transport of vesicles within the endoplasmic reticulum.

In addition to its role in cellular processes, MAP1LC3B2 is also a potential drug target. Because it has been shown to interact with several small molecules, including rapamycin, a drug that is commonly used to inhibit the activity of microtubule-associated proteins. This suggests that MAP1LC3B2 may be a good target for small molecule inhibitors.

MAP1LC3B2 is also a potential biomarker for a variety of diseases. For example, it has been shown to be elevated in the brains of individuals with Alzheimer's disease, a condition characterized by the progressive loss of brain cells. This suggests that MAP1LC3B2 may be a useful biomarker for the diagnosis and treatment of Alzheimer's disease.

In conclusion, MAP1LC3B2 is a protein that is expressed in a variety of tissues throughout the body and is involved in a variety of cellular processes. It is also a potential drug target and biomarker for a variety of diseases. Further research is needed to fully understand the role of MAP1LC3B2 in cellular processes and its potential as a drug and biomarker.

Protein Name: Microtubule Associated Protein 1 Light Chain 3 Beta 2

Functions: Ubiquitin-like modifier involved in formation of autophagosomal vacuoles (autophagosomes). Plays a role in mitophagy which contributes to regulate mitochondrial quantity and quality by eliminating the mitochondria to a basal level to fulfill cellular energy requirements and preventing excess ROS production. In response to cellular stress and upon mitochondria fission, binds C-18 ceramides and anchors autophagolysosomes to outer mitochondrial membranes to eliminate damaged mitochondria. While LC3s are involved in elongation of the phagophore membrane, the GABARAP/GATE-16 subfamily is essential for a later stage in autophagosome maturation

The "MAP1LC3B2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAP1LC3B2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets